Cell culture and neutralization have been considered the gold standard for enterovirus detection and identification for more than 50 years, but molecular amplification technologies are rapidly replacing the traditional methods in clinical and public health laboratories. Assays based on reverse transcription-polymerase chain reaction or nucleic acid sequence-based amplification may be used to detect enterovirus genome in all types of clinical specimens. More recently, nucleotide sequence has been used as a surrogate for antigenic typing (determination of serotype) by targeting parts of the enterovirus capsid-coding region that contain serotype-specific neutralization epitopes. This review will describe the molecular methods currently being used to diagnose enterovirus infection and disease, starting with the broadest level (family/genus detection) and proceeding through species/serotype identification to genotyping and molecular epidemiology. The commonly used molecular assays are usually more sensitive and more specific than cell culture and antigenic typing. They can reduce the turnaround time for testing of clinical diagnostic specimens to a clinically relevant timeframe and should supplant culture/neutralization as the gold standard in the near future. However, further evaluation and, in particular, more rigorous validation are required before a molecular diagnostic standard can be established. 
Introduction
Enteroviruses are among the most common of human viruses, infecting an estimated 50 million people annually in the USA and possibly a billion or more worldwide [1, 2] . Most infections are inapparent, but enteroviruses may cause a wide spectrum of acute disease, including mild upper respiratory illness (common cold), febrile rash (hand, foot and mouth disease and herpangina), aseptic meningitis, pleurodynia, encephalitis, acute flaccid paralysis (paralytic poliomyelitis), and neonatal sepsislike disease. While less than 1% of infections cause significant symptomatic illness, enterovirus infections result in 30 000 to 50 000 hospitalizations per year in the USA, with aseptic meningitis cases accounting for the vast majority of the hospitalizations [2] . In addition to these acute illnesses, enteroviruses have also been associated with severe chronic diseases including myocarditis and dilated cardiomyopathy [3] [4] [5] [6] , type 1 diabetes mellitus [7] [8] [9] , and neuromuscular diseases [10] .
The human enteroviruses were originally classified on the basis of human disease (polioviruses), replication and pathogenesis in newborn mice (coxsackie A and B viruses; CVA and CVB), and growth in cell culture without causing disease in mice (echoviruses; E), but they have recently been reclassified, based largely on molecular properties. In the current classification scheme (Table 1) , the genus is divided into eight species: (i) Poliovirus (PV; PV1 to PV3); (ii) Human enterovirus A (HEV-A; CVA2 to CVA8, CVA10, CVA12, CVA14, CVA16 and EV71); (iii) Human enterovirus B (HEV-B; CVA9, CVB1 to CVB6, E1 to E7, E9, E11 to E21, E24 to E27, E29 to E33 and EV69); (iv) Human enterovirus C (HEV-C; CVA1, CVA11, CVA13, CVA17, CVA19 to CVA22, and CVA24); (v) Human enterovirus D (HEV-D; EV68 and EV70); (vi) Bovine enterovirus (BEV; BEV1 and 2); (vii) Porcine enterovirus B (PEV; PEV9 and 10); and (viii) Simian enterovirus A (SEV-A; simian virus 4). Recent phylogenetic studies suggest that polioviruses should be reclassified as members of HEV-C [11] . Several new serotypes, members of HEV-A (EV76 and EV89-91) and HEV-B (EV73-75 and EV77-78), have been described recently [12] [13] [14] [15] [16] and many additional new serotypes are currently being characterized (through EV101) in several laboratories.
Specimens of choice for the direct detection of enteroviruses are stool or rectal swab (stool is preferred over swabs because it contains a larger amount of fecal material and, hence, virus); oro-or nasopharyngeal specimens (throat swab, nasopharyngeal swab or aspirate); cerebrospinal fluid (CSF; if there is concomitant central nervous system disease); and fresh-frozen or formalinfixed tissue. Serum and plasma are generally useful specimens only in infants, where viremia may still be present after onset of symptoms. Because enteroviruses are ubiquitous and asymptomatic carriage is common, detection of virus only in a non-sterile site, such as stool or nasopharynx, cannot be considered a definitive identification of the etiology of disease. In the absence of alternative etiologies and with typical clinical presentation (e.g., aseptic meningitis), any detection might be considered presumptive evidence of etiology.
Originally, enterovirus disease was diagnosed by virus isolation in suckling mice or cell culture, followed by identification by neutralization with serotype-specific antisera. Because virus isolation and neutralization are labor-intensive and time-consuming, rarely producing results within a clinically relevant timeframe, molecular methods have been developed for enterovirus detection. However, there is no Food and Drug Administration (FDA)-approved (or other standard) diagnostic test available for clinical use. As a result, there is a diverse array of in-house methods which vary widely in sensitivity, specificity, and degree of validation. The most common assays are all based on primer-mediated enzymatic amplification of viral nucleic acid by reverse transcription (RT)-polymerase chain reaction (PCR) or nucleic acid sequence-based amplification (NASBA). In these assays, amplification may be coupled with probe hybridization (in liquid-or solid-phase) to increase sensitivity or specificity or to facilitate product detection. They may also incorporate a second (nested or seminested) round of amplification which increases both sensitivity and specificity, or the product may be sequenced to confirm specificity or allow serotype identification. The choice of assay is determined by the desired level of sensitivity and specificity. These, in turn are influenced by the needs of the clinician to inform clinical case management, or the needs of public health officials to guide control efforts. Since the enterovirus serotype is rarely relevant to clinical case management, the clinician may need to know only whether enterovirus is present, for example, to determine in conjunction with other laboratory findings whether empirical antibiotic treatment could be discontinued. On the other hand, researchers or public health authorities may want to know virus serotype during an outbreak, to determine which cases are epidemiologically linked, for surveillance purposes, or for disease-association studies.
This review will address the four basic diagnostic questions in viral (in particular, enteroviral) disease investigation: (i) is a virus present? (pathogen yes/no); (ii) if so, is it an enterovirus? (rather than a herpesvirus, adenovirus, etc.; that is, family/genus identification); and (iii) if an enterovirus, which one? (species/serotype). We will describe molecular amplification assays that have been developed to answer each question.
Pathogen detection
Electron microscopy and culture remain the only completely generic tests to determine whether an infectious agent is present in a clinical specimen. That is, other assay methods generally are designed to detect a specific pathogen, through the use of pathogen-specific reagents. Recently, molecular methods such as representational difference analysis and microarray analysis have been used to more generically detect non-host sequences in clinical specimens [17] [18] [19] [20] [21] but these methods, in their current form, are either labor-intensive, expensive, or require specialized instrumentation, so they have not yet been widely applied in routine diagnostic virology. However, they may eventually find a role in the diagnostic laboratory as future improvements improve sensitivity, bring down costs and increase usability.
Family/genus identification
While virus isolation has long been the gold standard in enterovirus diagnostics, the application of PCR has improved the speed and accuracy of enterovirus detection Several previously defined types are omitted because they are reclassified or proposed for reclassification: coxsackievirus (CV)A15 is a strain of CVA11; CVA18 is a strain of CVA13; CVA23 is a strain of E9; E8 is a strain of E1; E10 is human reovirus 1 (genus Orthoreovirus, family Reoviridae), E22-23 are human parechoviruses 1 and 2, respectively (genus Parechovirus, family Picornaviridae); E28 is human rhinovirus 1A (genus Rhinovirus, family Picornaviridae); EV72 is human hepatitis A virus (genus Hepatovirus, family Picornaviridae) [61] . PV, poliovirus; E, echovirus.
[22 -24] . As a result, molecular diagnostic assays have found wide acceptance in the clinical diagnostic laboratory. Since the enterovirus serotype is rarely relevant to individual clinical case management, many clinical virology laboratories are bypassing virus isolation entirely, in favor of PCR detection of viral nucleic acid directly in clinical specimens such as CSF, nasopharyngeal swabs, or tissue specimens [22] . The most common approach uses genus-specific primers targeted to the 5 0 non-translated region (NTR) [22] . The 5 0 -NTR is the most highly conserved region of the genome, due to its essential role in directing cap-independent viral protein translation. Three conveniently sized sites that are fully conserved among all enteroviruses are available for primer/probe design (labeled sites 2-4 in Fig. 1 ). The majority of 'pan-enterovirus' primers and probes are designed to take advantage of the near-absolute conservation at these three sites. For example, all of the published enterovirus real-time RT-PCR methods target these sites, usually with primers that anneal to sites 2 and 4, and a probe that recognizes site 3 [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] but, in one of the methods, both the probe and reverse primer target portions of site 3 [36] . One of the three published NASBA methods also targets sites 2-4, but the other two methods target the somewhat less well conserved sites 1 and 5 for the amplification step and site 2 or site 3 for probe annealing [37, 38] . These two methods would still be expected to amplify most enteroviruses but the sensitivity might be reduced for certain viruses because of multiple mismatches in the priming sites; presumably, the reduced sensitivity could cause false-negative results, particularly in original specimens with low virus titer. Otherwise, the NASBA assays are similar in absolute sensitivity to the real-time PCR methods; none of these three NASBA methods uses a 'real-time' detection. A real-time NASBA method was recently published, using a commercial kit for which the primers and probe are not disclosed, but the method was not validated using specimens of known enterovirus serotype [39] . Furthermore, the real-time NASBA method failed to detect enteroviral RNA in five of 91 clinical specimens that were RT-PCR-positive using a single-step PCR with gelbased detection.
Site 2 and part of site 3 are well conserved between enteroviruses and rhinoviruses, resulting in cross-amplification when particular primer sets are used [40] . This point is important to consider when respiratory specimens are being tested, since both enteroviruses and rhinoviruses may be found in the respiratory tract. However, the two groups can be distinguished using specific probes [36, 40] . Given the primer and probe sites used by the real-time assays, one would expect them to be enterovirus-specific, but only Kares et al. [36] and Nijhuis et al. [30] have explicitly tested for cross-reaction with rhinoviruses.
All of the molecular methods are superior to cell culture in absolute sensitivity for most, if not all enteroviruses, detecting less than one 50% cell culture infectious dose (CCID 50 ; amount of virus required to cause cytopathic effect in 50% of inoculated cultures) and several have a reported absolute sensitivity of less than 20 copies of viral RNA [29, 34, 35] . Studies have also consistently shown pan-enterovirus 5 0 -NTR-specific RT-PCR or NASBA to be at least as sensitive as culture for detecting enterovirus in patients with clinically diagnosed aseptic meningitis [37, 38, [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] .
The original enterovirus PCR assays, developed 10-15 years ago, were constrained by a lack of sequence data to facilitate primer design. Most targeted the 5 0 -NTR, but they were poorly validated. Sequence data published subsequently have shown that many of the primer sets would be predicted to amplify only a limited range of viruses. The more recently published assays have benefited from the availability of a large sequence set from which to select primers and all of the published realtime PCR methods would be expected to amplify most, if not all enteroviruses. However, most of these are still not well validated experimentally. In fact, only one of the nine 5 0 -NTR assays shown in Fig. 1 was validated using over half of the enterovirus prototype strains [30] . For all of the assays, a positive result is a reliable indicator that enterovirus RNA is present in the specimen; that is, they have a high positive predictive value and an enterovirus-positive CSF in a patient with meningeal symptoms confirms the diagnosis of enterovirus meningitis. However, a negative PCR result, even with an assay of high analytical sensitivity, cannot necessarily be used to rule out enterovirus infection. If an assay uses primers outside the most conserved sites (sites 2-4) and if the assay has not been validated using a comprehensive panel of prototype strains, any negative result must be considered uninterpretable. From the perspective of limited serotype detection, even relatively rare serotypes (those reported in less than 1% of cases) may collectively account for a significant fraction of all enterovirus infections [51] .
Even in acute illnesses, enterovirus titer is typically relatively low in all specimens. As a result, 'conventional' single-step RT-PCR amplification may not be sensitive enough for direct detection of virus in an original clinical specimen, even with the added sensitivity of a fluorogenic probe, as in the real-time methods. To address this specimen sensitivity issue, several nested or semi-nested RT-PCR assays that target the conserved regions of the 5 0 NTR have been developed [52] [53] [54] [55] [56] . These assays are up to four logs more sensitive than a single-step RT-PCR [56] and generally in the same range of absolute sensitivity as the real-time assays, but the nested and realtime methods have not yet been compared directly. Like the real-time PCR assays, the nested PCR methods have been validated to varying degrees, using prototype strains and clinical specimens. However, the nested PCR assays are not equivalent to the real-time methods in primer selection; for example, the Kämmerer assay uses two primers from outside the conserved 'core' sites [52] . Likewise, the Nicholson, Takami, and Palacios Poggio assays use one primer from outside the conserved core [53] [54] [55] . The use of suboptimal primers suggests that these methods may occasionally fail to amplify certain mismatched templates, resulting in false-negative results and a negative predictive value that is largely undefined. This observation underscores the importance of extensive validation using the widest possible array of reference strains (prototype and clinical strains) to ensure amplification and detection of even the most divergent templates in clinical specimens. A major disadvantage of the nested methods is the requirement to open the reaction tube to set up the second amplification. Extreme care must be taken to avoid cross-contamination of specimens or contamination of specimens with control materials. On the other hand, the nested methods provide the opportunity to sequence the amplification product, providing additional confirmation of the reaction specificity [56] . This confirmation is especially important when testing tissue specimens because the high level of non-viral nucleic acids may sometimes lead to false-positive results.
Species and serotype differentiation
Sequences in all genome regions, other than the 5 0 -NTR, correlate with enteroviral species [11, [57] [58] [59] [60] . Recognition of these relationships has led to the incorporation of sequence comparisons into the picornavirus taxonomic classification scheme [61] . In theory, sequences in any of these regions could be used to develop a diagnostic test to identify the species of a given virus and primers could be designed to target relatively conserved regions in the non-capsid sequences or 3 0 -NTR. Such a test might be useful in screening a large collection of isolates to identify isolates of interest for a particular study but, in practice, capsid region sequence may be preferable since it can yield both species and serotype information.
Enterovirus infection elicits a serotype-specific immune response directed against epitopes on the surface of the viral capsid. Humoral immunity is most important; antibody alone fully protects from disease, probably by limiting virus spread from the gut, but antibody does not necessarily protect from infection. The virus-specific Tcell response, directed against epitopes on both the structural and non-structural proteins, may be involved in virus clearance but it is not needed for protection. The serotype-specific properties of an enterovirus are encoded in the viral capsid. Antigenic sites are located in each of the three major enterovirus structural proteins, VP1, VP2, and VP3 [62, 63] , but the epitopes responsible for serotype specificity have not been explicitly identified. In treating the individual patient, identification of the infecting enterovirus serotype is usually relevant only in managing the immunocompromised patient, where immune globulin may be used to treat a persistent infection and antibody levels to the specific serotype are prognostic [64] . However, knowledge of enterovirus serotype can be very important in epidemiologic investigations, to determine whether specific cases are epidemiologically linked, to identify transmission patterns, and to ascertain the extent of an outbreak.
Traditionally, enteroviruses have been serotyped by the antigenic properties of the capsid using standardized antisera in a neutralization test [65] , but this method requires a virus isolate, is labor-intensive and timeconsuming, and is subject to numerous pitfalls that can result in mistyping or failure to determine a serotype [13] . Several genome regions have been targeted in the development of molecular serotyping assays, largely on the basis of the location of conserved sites to facilitate the design of amplification primers. The 5 0 -NTR was initially targeted because the sequences are highly conserved; however, this region was found to be unsuitable for serotype identification because RNA recombination tends to delink the capsid region from the flanking genome regions, including the 5 0 -NTR and Enterovirus molecular detection and typing Oberste and Pallansch 167 [32] , Monpoeho [26] , Lai [25] , Corless [28] , Mohamed [29] , and Kares [36] . The consensus sequence at each site and the sequences of the widely used Rotbart primers and probe [48] are indicated for comparison. Mismatches between a primer and the human enterovirus consensus are underlined. Numbers indicate nucleotide positions relative to the genome of poliovirus 1, Mahoney strain (GenBank J02281). (b) Sequence conservation at sites in the EV 5 0 -NTR that are targeted by the published nucleic acid sequence-based amplification (NASBA) methods of Heim [50] , Fox [37] , and Landry [38] , as in (a). (c) Nucleotide sequence variation across the enterovirus genome. Complete genome sequences for reference strains of all human enterovirus serotypes were aligned and the sequence identity within each window of 18 residues was plotted versus the nucleotide position and the window was advanced in one-residue increments across the genome. An expanded view of the 5 0 -NTR analysis is shown in the upper plot. Peaks labeled 1-5 are sites commonly targeted by enterovirus molecular detection assays. (d) Enterovirus genome map. Boundaries of mature protein products are approximate. (e) Amino acid sequence variation across the enterovirus genome. Deduced polyprotein amino acid sequences for reference strains of all human enterovirus serotypes were aligned; the sequence identity within each window of six residues was plotted versus the amino acid position and the window was advanced in one-residue increments across the genome. (f) Locations of RT-PCR products used for molecular serotyping by Oberste [13, 76, 81] , Caro [78] , Norder [77] , Casas [66] , and Thoelen [79] .
regions encoding the viral non-structural proteins [66, 67] . Sequences in various portions of the enterovirus coding region correlate with species, but only capsid sequence correlates with serotype, since sites outside the capsidcoding region may be exchanged by viruses of different serotype via intraspecies RNA recombination [11, 60, [67] [68] [69] [70] [71] . For this reason, sequence information from noncapsid regions is of little value in identifying serotypes within known species. Recombination may also occur near the boundaries of the capsid-coding region but the bulk of the capsid region is inherited as a single unit.
Sequences surrounding the VP4-VP2 junction have been used for molecular typing [72] [73] [74] , but this region has been shown to be less reliable for serotype identification [66] . Since the picornavirus VP1 protein contains a number of immunodominant neutralization domains, we hypothesized that VP1 sequence should correspond with neutralization properties (serotype) [75] . We and others have shown that complete or partial VP1 sequence correlates completely with antigenic typing by neutralization assay and that it may serve as a molecular surrogate for traditional serotyping methods [13, 14, 66, [75] [76] [77] [78] [79] .
Because of the degeneracy of the genetic code (one amino acid may be specified by from one to six different triplet codons) and the high enterovirus sequence diversity, targets in the coding region are best conceptualized as conserved amino acid sequences from which oligonucleotide primer sequences may be derived by backtranslation. Codon degeneracy and sequence diversity, even within a serotype, necessitate the use of degenerate primers or multiple primer pairs to amplify all enterovirus serotypes. Even with the use of multiple non-degenerate or minimally degenerate primers, it is difficult to design 'pan-enterovirus' primers that can be used for VP1 sequencing and molecular serotyping. Two of the published methods explicitly target only members of HEV-B, in order to reduce the number of unique primers required [77, 79] . Caro et al. reduced the number of primers in their assay by targeting the cis-acting replication element, a site in 2C that is highly conserved in both secondary and primary sequence [80] , pairing three 2C primers with three in VP1 [78] . Our strategy has been to design degenerate primers that contain deoxyinosine residues at positions of fourfold codon degeneracy (e.g., using GGI to specify a glycine codon, normally GGN) [13, 76, 81] . For example, our currentgeneration primers target the conserved VP1 amino acid motifs (QT)A(AV)ETG and M(FY)(IV)PPG(AG), where alternative residues at a given site are within parentheses, using the primers MIGCIGYIGARACNGG and CIC-CIGGIGGIAYRWACAT, respectively (I=deoxyinosine; M=A or C; N=A, C, G, or T; R=A or G; W=A or T; and Y=C or T) [81] . These primers amplify RNA templates from all human enterovirus serotypes, as well as some human rhinoviruses. Casas et al. have used a similar approach, using degenerate, deoxyinosine-containing primers to target a different part of VP1 [66] .
Several PCR assays have been developed to allow serotype identification directly from original clinical specimens by nested amplification and sequencing of VP1 [56, 66, 79] . The nested amplification format increases sensitivity substantially, rivaling the sensitivity of the nested 5 0 -NTR assays [56, 66] , so that nested VP1 assays can be used for both detection and identification. Nonspecific amplification can sometimes occur when degenerate primers are used in a nested PCR assay, particularly when amplifying from nucleic acids isolated from tissues or other high-complexity specimens and therefore the presence of an amplification product in these reactions, even of the correct size, is not diagnostic of the presence of an enterovirus without sequence confirmation. Additional work is needed in this area to increase assay specificity without sacrificing sensitivity.
The basic analysis method for molecular serotyping is to compare the sequence derived from the patient to a database containing the homologous sequence from all known enterovirus serotypes and identify the serotype based on the similarity of the query sequence to a particular sequence in the database. Two approaches have been used to compare VP1 sequences for molecular typing: the phylogenetic method and the pairwise comparison method. The phylogenetic method lends itself to analysis of a large number of sequences because sequences are compared in a multiple sequence alignment rather than individually, but the interpretation is subjective, relying on manual determination of whether the query sequence is 'in' or 'out' of a particular 'cluster.' Nevertheless, the phylogenetic method is usually sufficient if the query sequence is relatively closely related to a database sequence [66, [77] [78] [79] . By contrast, the pairwise method yields a quantitative measure of the similarity of the query sequence to a reference sequence, usually in the form of an identity score. A large number of sequences may be accommodated in this method by using a 'multiple sequence alignment' algorithm to form a large alignment of all query and database sequences [66, 77, 82] . In a multiple alignment, the overall alignment of all sequences is optimized but there is no guarantee that the alignment between any two given sequences is optimal. As a result, this method may sometimes underestimate the identity between two sequences [82] . Another way to analyze multiple query sequences is to write a simple script to automate the comparison of each query sequence to each database sequence, guaranteeing that each alignment is optimal for the algorithm and parameters used [13, 75, 76] .
To facilitate serotype identification of unknowns, we have recommended specific criteria for the interpretation of VP1 sequence data using pairwise identity scores [13, 14, 76, 81] . A partial or complete VP1 nucleotide sequence identity of at least 75% (minimum 85% amino acid sequence identity) between a clinical enterovirus sequence and a serotype prototype strain may be used to establish the serotype of the isolate [13, 75, 76] . A bestmatch nucleotide sequence identity of between 70 and 75% or a second-highest score of greater than 70% may provide a tentative identification, pending confirmation by other means, such as neutralization with monospecific antisera [13] or more extensive sequencing. A best-match nucleotide sequence identity below 70% (or less than 85% amino acid sequence identity) may indicate that the isolate represents an unknown (i.e., new) serotype [13, 14] . Sequencing of the complete capsid-coding region may be useful in confirming this result. More extensive characterization, possibly including complete genome sequences, may be required for viruses that appear to represent previously unknown species or genera [83] [84] [85] [86] .
So far, all VP1 PCR-sequencing assays appear to be functionally equivalent, provided a product is amplified. That is, sequences from several different portions of VP1 appear to correctly identify the serotype. However, only four of the methods have been validated using all 64 accepted human enterovirus serotypes [13, 76, 78, 81] and only two of these have been shown to successfully amplify all human enterovirus serotypes [13, 81] . Caro et al. [78] , Casas et al. [66] , Norder et al. [77] , and Oberste et al. [13, 76] have also validated their assays using clinical isolates typed by neutralization and representing a limited number of common serotypes.
In addition to generic serotype identification by sequencing of the capsid-coding region, a number of serotype-specific primer pairs have been developed for use in special circumstances. For example, PCR primers that specifically amplify all polioviruses [87] , or each of the three poliovirus serotypes individually [88] are widely used by laboratories in the Global Polio Laboratory Network to identify polioviruses isolated from paralyzed children, in support of the Global Polio Eradication Initiative [89] . Additional serotype-specific primers have been developed to facilitate screening for serotypes of interest during outbreaks of aseptic meningitis, acute hemorrhagic conjunctivitis, or hand, foot, and mouth disease; these serotypes include E11 [90] , E13 [91] , E30 [92] , E33 [93] , EV70 [94] , CVA16 [95] , and EV71 [96] . Serotype-specific primers may be useful during an outbreak as a screening tool to quickly determine whether a given case is likely to be epidemiologically linked to other cases, enabling public health authorities to focus attention on 'outbreak cases' and ignore sporadic cases of other co-circulating serotypes.
Conclusions
Molecular methods are available that can be used for the sensitive detection and identification of enteroviral RNA in clinical specimens. These assays are designed in a variety of formats that are easily integrated in the routine of most diagnostic laboratories. The published methods, however, vary widely in the degree of validation through both analytical and clinical evaluations (ability to detect specific viruses and positive/negative predictive value given a specific clinical presentation, respectively). Further careful and extensive validation will be necessary to fully establish a new, molecular, gold standard for the diagnosis of enteroviral infection.
